Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment.

Roy Chowdhury S, Bouchard EDJ, Saleh R, Nugent Z, Peltier C, Mejia E, Hou S, McFall C, Squires M, Hewitt D, Davidson L, Shen GX, Johnston JB, Doucette C, Hatch GM, Fernyhough P, Marshall A, Gibson SB, Dawe DE, Banerji V.

Cancers (Basel). 2020 Mar 11;12(3). pii: E650. doi: 10.3390/cancers12030650.

2.

Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report.

Streu E, Wiseman MC, Johnston JB.

SAGE Open Med Case Rep. 2020 Jan 21;8:2050313X19901071. doi: 10.1177/2050313X19901071. eCollection 2020.

3.

Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.

Uminski K, Brown K, Bucher O, Hibbert I, Dhaliwal DH, Johnston JB, Geirnaert M, Dawe DE, Banerji V.

Curr Oncol. 2019 Oct;26(5):e610-e617. doi: 10.3747/co.26.4957. Epub 2019 Oct 1.

4.

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia.

Kost SEF, Saleh A, Mejia EM, Mostafizar M, Bouchard EDJ, Banerji V, Marshall AJ, Gibson SB, Johnston JB, Katyal S.

Cancers (Basel). 2019 Oct 9;11(10). pii: E1519. doi: 10.3390/cancers11101519.

5.

Buccal cell telomere length is not a useful marker for comorbidities in chronic lymphocytic leukemia.

Yang L, Kost SEF, Beiggi S, Zhang Y, Schmidt R, Nugent Z, Marshall A, Banerji V, Gibson SB, Johnston JB.

Leuk Res. 2019 Nov;86:106220. doi: 10.1016/j.leukres.2019.106220. Epub 2019 Aug 28. No abstract available.

PMID:
31499418
6.

The Gene-Silencing Protein MORC-1 Topologically Entraps DNA and Forms Multimeric Assemblies to Cause DNA Compaction.

Kim H, Yen L, Wongpalee SP, Kirshner JA, Mehta N, Xue Y, Johnston JB, Burlingame AL, Kim JK, Loparo JJ, Jacobsen SE.

Mol Cell. 2019 Aug 22;75(4):700-710.e6. doi: 10.1016/j.molcel.2019.07.032.

PMID:
31442422
7.

IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.

Ishdorj G, Streu E, Lambert P, Dhaliwal HS, Mahmud SM, Gibson SB, Banerji V, Marshall AJ, Johnston JB.

Blood Adv. 2019 Jul 23;3(14):2188-2198. doi: 10.1182/bloodadvances.2018026591.

8.

Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival.

Ishdorj G, Beiggi S, Nugent Z, Streu E, Banerji V, Dhaliwal D, Mahmud SM, Marshall AJ, Gibson SB, Wiseman MC, Johnston JB.

Leuk Lymphoma. 2019 Dec;60(13):3204-3213. doi: 10.1080/10428194.2019.1620941. Epub 2019 Jun 25.

PMID:
31237469
9.

Statin Use and Chronic Lymphocytic Leukemia Incidence: A Nested Case-Control Study in Manitoba, Canada.

Righolt CH, Zhang G, Ye X, Banerji V, Johnston JB, Gibson S, Mahmud SM.

Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1495-1501. doi: 10.1158/1055-9965.EPI-19-0107. Epub 2019 Jun 11.

PMID:
31186266
10.

Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.

Ali AY, Guan Q, Wu X, Hou S, Banerji V, Johnston JB, Wall D, Szwajcer D, Gibson SB, Marshall AJ.

Br J Haematol. 2019 Jun;185(5):883-887. doi: 10.1111/bjh.15865. Epub 2019 Mar 14.

PMID:
30873593
11.

A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).

Chen CI, Paul H, Snitzler S, Kakar S, Le LW, Wei EN, Lau A, Johnston JB, Gibson SB, Queau M, Spaner D, Croucher D, Sherry B, Trudel S.

Leuk Lymphoma. 2019 Apr;60(4):980-989. doi: 10.1080/10428194.2018.1508669. Epub 2018 Oct 2.

PMID:
30277089
12.

A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).

Chen CI, Paul H, Le LW, Wei EN, Snitzler S, Wang T, Levina O, Kakar S, Lau A, Queau M, Johnston JB, Smith DA, Trudel S.

Leuk Lymphoma. 2019 Jan;60(1):92-100. doi: 10.1080/10428194.2018.1468892. Epub 2018 Jun 19.

PMID:
29916761
13.

Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells.

Das S, Dielschneider R, Chanas-LaRue A, Johnston JB, Gibson SB.

Leuk Res. 2018 Jul;70:79-86. doi: 10.1016/j.leukres.2018.06.005. Epub 2018 Jun 7.

PMID:
29902707
14.

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Kleinstern G, Camp NJ, Goldin LR, Vachon CM, Vajdic CM, de Sanjose S, Weinberg JB, Benavente Y, Casabonne D, Liebow M, Nieters A, Hjalgrim H, Melbye M, Glimelius B, Adami HO, Boffetta P, Brennan P, Maynadie M, McKay J, Cocco PL, Shanafelt TD, Call TG, Norman AD, Hanson C, Robinson D, Chaffee KG, Brooks-Wilson AR, Monnereau A, Clavel J, Glenn M, Curtin K, Conde L, Bracci PM, Morton LM, Cozen W, Severson RK, Chanock SJ, Spinelli JJ, Johnston JB, Rothman N, Skibola CF, Leis JF, Kay NE, Smedby KE, Berndt SI, Cerhan JR, Caporaso N, Slager SL.

Blood. 2018 Jun 7;131(23):2541-2551. doi: 10.1182/blood-2017-11-814608. Epub 2018 Apr 19.

15.

Associations between statin use and risk of non-Hodgkin lymphomas by subtype.

Ye X, Zhang G, Righolt C, Johnston JB, Banerji V, Gibson SB, Mahmud SM.

Int J Cancer. 2018 Aug 15;143(4):971-979. doi: 10.1002/ijc.31373. Epub 2018 Mar 30.

16.

Metformin Is Not Associated with Incidence Risk of Non-Hodgkin Lymphomas among Diabetic Patients.

Ye X, Zhang G, Righolt C, Johnston JB, Banerji V, Gibson SB, Mahmud SM.

Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):610-612. doi: 10.1158/1055-9965.EPI-18-0012. Epub 2018 Mar 6.

17.

Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.

Ali AY, Wu X, Eissa N, Hou S, Ghia JE, Murooka TT, Banerji V, Johnston JB, Lin F, Gibson SB, Marshall AJ.

Leukemia. 2018 Sep;32(9):1958-1969. doi: 10.1038/s41375-018-0012-5. Epub 2018 Jan 31.

18.

Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine.

Perry AM, Matsuda K, Wadhwa V, Hewitt D, Almiski M, Johnston JB, Banerji V.

Blood Adv. 2017 May 30;1(14):899-902. doi: 10.1182/bloodadvances.2017004697. eCollection 2017 Jun 13.

19.

Observational study of the populations accessing rapid point-of-care HIV testing in Winnipeg, Manitoba, Canada, through a retrospective chart review of site records.

Johnston JB, Reimer JN, Wylie JL, Bullard J.

Sex Transm Infect. 2018 May;94(3):194-199. doi: 10.1136/sextrans-2017-053195. Epub 2017 Oct 7.

PMID:
28988194
20.
21.

Liquid droplet formation by HP1α suggests a role for phase separation in heterochromatin.

Larson AG, Elnatan D, Keenen MM, Trnka MJ, Johnston JB, Burlingame AL, Agard DA, Redding S, Narlikar GJ.

Nature. 2017 Jul 13;547(7662):236-240. doi: 10.1038/nature22822. Epub 2017 Jun 21.

22.

Regulation of Rvb1/Rvb2 by a Domain within the INO80 Chromatin Remodeling Complex Implicates the Yeast Rvbs as Protein Assembly Chaperones.

Zhou CY, Stoddard CI, Johnston JB, Trnka MJ, Echeverria I, Palovcak E, Sali A, Burlingame AL, Cheng Y, Narlikar GJ.

Cell Rep. 2017 Jun 6;19(10):2033-2044. doi: 10.1016/j.celrep.2017.05.029.

23.

A novel spliced variant of the TIN2 shelterin is present in chronic lymphocytic leukemia.

Ishdorj G, Kost SEF, Beiggi S, Zang Y, Gibson SB, Johnston JB.

Leuk Res. 2017 Aug;59:66-74. doi: 10.1016/j.leukres.2017.05.017. Epub 2017 May 29.

PMID:
28575699
24.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

25.

Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.

Kost SE, Bouchard ED, LaBossière É, Ye X, Queau ML, Liang WS, Banerji V, Gibson SB, Katyal S, Johnston JB.

Leuk Res. 2016 Nov;50:63-71. doi: 10.1016/j.leukres.2016.09.016. Epub 2016 Sep 20.

PMID:
27683974
26.

Mouse MORC3 is a GHKL ATPase that localizes to H3K4me3 marked chromatin.

Li S, Yen L, Pastor WA, Johnston JB, Du J, Shew CJ, Liu W, Ho J, Stender B, Clark AT, Burlingame AL, Daxinger L, Patel DJ, Jacobsen SE.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5108-16. doi: 10.1073/pnas.1609709113. Epub 2016 Aug 15.

27.

Comparison of outcome of patients with CLL who are referred or nonreferred to a specialized CLL clinic: a Canadian population-based study.

Beiggi S, Banerji V, Deneka A, Griffith J, Gibson SB, Johnston JB.

Cancer Med. 2016 Jun;5(6):971-9. doi: 10.1002/cam4.559. Epub 2016 Feb 18.

28.

Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism.

Dielschneider RF, Eisenstat H, Mi S, Curtis JM, Xiao W, Johnston JB, Gibson SB.

Leukemia. 2016 Jun;30(6):1290-300. doi: 10.1038/leu.2016.4. Epub 2015 Feb 23.

PMID:
26859075
29.

Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes.

Li H, Wu X, Hou S, Malek M, Kielkowska A, Noh E, Makondo KJ, Du Q, Wilkins JA, Johnston JB, Gibson SB, Lin F, Marshall AJ.

J Immunol. 2016 Jan 15;196(2):586-95. doi: 10.4049/jimmunol.1500630. Epub 2015 Dec 22.

30.

Clinical features and diagnosis of hairy cell leukemia.

Quest GR, Johnston JB.

Best Pract Res Clin Haematol. 2015 Dec;28(4):180-92. doi: 10.1016/j.beha.2015.10.017. Epub 2015 Oct 26. Review.

PMID:
26614896
31.

Associations between statin use and non-Hodgkin lymphoma (NHL) risk and survival: a meta-analysis.

Ye X, Mneina A, Johnston JB, Mahmud SM.

Hematol Oncol. 2017 Jun;35(2):206-214. doi: 10.1002/hon.2265. Epub 2015 Oct 20. Review.

PMID:
26482323
32.

Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia.

Kriangkum J, Motz SN, Mack T, Beiggi S, Baigorri E, Kuppusamy H, Belch AR, Johnston JB, Pilarski LM.

PLoS One. 2015 Sep 9;10(9):e0137232. doi: 10.1371/journal.pone.0137232. eCollection 2015.

33.

Enhancing monoclonal antibody activity in chronic lymphocytic leukemia.

Johnston JB.

Leuk Lymphoma. 2015;56(8):2231-2. Epub 2015 Sep 18. No abstract available.

PMID:
26247301
34.

Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.

Beauchemin C, Johnston JB, Lapierre MÈ, Aissa F, Lachaine J.

Curr Oncol. 2015 Jun;22(3):e148-56. doi: 10.3747/co.22.2119.

35.

Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70.

Lafarge ST, Hou S, Pauls SD, Johnston JB, Gibson SB, Marshall AJ.

Leuk Res. 2015 Jul;39(7):773-8. doi: 10.1016/j.leukres.2015.04.016. Epub 2015 May 2.

PMID:
26002513
36.

Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase.

McCall LI, El Aroussi A, Choi JY, Vieira DF, De Muylder G, Johnston JB, Chen S, Kellar D, Siqueira-Neto JL, Roush WR, Podust LM, McKerrow JH.

PLoS Negl Trop Dis. 2015 Mar 13;9(3):e0003588. doi: 10.1371/journal.pntd.0003588. eCollection 2015 Mar.

37.

CholMine: Determinants and Prediction of Cholesterol and Cholate Binding Across Nonhomologous Protein Structures.

Liu N, Van Voorst JR, Johnston JB, Kuhn LA.

J Chem Inf Model. 2015 Apr 27;55(4):747-59. doi: 10.1021/ci5006542. Epub 2015 Mar 24.

PMID:
25760928
38.

Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.

Vieira DF, Choi JY, Calvet CM, Siqueira-Neto JL, Johnston JB, Kellar D, Gut J, Cameron MD, McKerrow JH, Roush WR, Podust LM.

J Med Chem. 2014 Dec 11;57(23):10162-75. doi: 10.1021/jm501568b. Epub 2014 Nov 25.

39.

Biologically active polymers from spontaneous carotenoid oxidation: a new frontier in carotenoid activity.

Johnston JB, Nickerson JG, Daroszewski J, Mogg TJ, Burton GW.

PLoS One. 2014 Oct 31;9(10):e111346. doi: 10.1371/journal.pone.0111346. eCollection 2014.

40.

Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.

Dielschneider RF, Xiao W, Yoon JY, Noh E, Banerji V, Li H, Marshall AJ, Johnston JB, Gibson SB.

Cell Death Dis. 2014 Oct 2;5:e1439. doi: 10.1038/cddis.2014.391.

41.

On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.

Gehrke I, Bouchard ED, Beiggi S, Poeppl AG, Johnston JB, Gibson SB, Banerji V.

Clin Cancer Res. 2014 Sep 15;20(18):4861-72. doi: 10.1158/1078-0432.CCR-14-0624. Epub 2014 Aug 29.

42.

4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.

Calvet CM, Vieira DF, Choi JY, Kellar D, Cameron MD, Siqueira-Neto JL, Gut J, Johnston JB, Lin L, Khan S, McKerrow JH, Roush WR, Podust LM.

J Med Chem. 2014 Aug 28;57(16):6989-7005. doi: 10.1021/jm500448u. Epub 2014 Aug 19.

43.

ZAP70 expression directly promotes chronic lymphocytic leukaemia cell adhesion to bone marrow stromal cells.

Lafarge ST, Li H, Pauls SD, Hou S, Johnston JB, Gibson SB, Marshall AJ.

Br J Haematol. 2015 Jan;168(1):139-42. doi: 10.1111/bjh.13063. Epub 2014 Aug 4. No abstract available.

PMID:
25088442
44.

Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.

Kuppusamy H, Ogmundsdottir HM, Baigorri E, Warkentin A, Steingrimsdottir H, Haraldsdottir V, Mant MJ, Mackey J, Johnston JB, Adamia S, Belch AR, Pilarski LM.

PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.

45.

Hepatitis B and hepatitis C viral infections in patients with chronic lymphocytic leukemia.

Minuk GY, Lerner B, Gibson SB, Johnston JB, Uhanova J, Andonov A, Wu J.

Can J Gastroenterol Hepatol. 2014 Mar;28(3):131-4.

46.

Comparison of droperidol and haloperidol for use by paramedics: assessment of safety and effectiveness.

Macht M, Mull AC, McVaney KE, Caruso EH, Johnston JB, Gaither JB, Shupp AM, Marquez KD, Haukoos JS, Colwell CB.

Prehosp Emerg Care. 2014 Jul-Sep;18(3):375-80. doi: 10.3109/10903127.2013.864353. Epub 2014 Jan 24.

47.

Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B.

Yoon JY, Szwajcer D, Ishdorj G, Benjaminson P, Xiao W, Kumar R, Johnston JB, Gibson SB.

Blood Cancer J. 2013 Oct 18;3:e153. doi: 10.1038/bcj.2013.50.

48.

Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.

Yoon JY, Ishdorj G, Graham BA, Johnston JB, Gibson SB.

Apoptosis. 2014 Jan;19(1):191-200. doi: 10.1007/s10495-013-0906-7.

PMID:
24057147
49.

Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.

Lafarge ST, Johnston JB, Gibson SB, Marshall AJ.

Leuk Res. 2014 Jan;38(1):109-15. doi: 10.1016/j.leukres.2013.08.001. Epub 2013 Aug 9.

50.

Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.

Shawi M, Chu TW, Martinez-Marignac V, Yu Y, Gryaznov SM, Johnston JB, Lees-Miller SP, Assouline SE, Autexier C, Aloyz R.

PLoS One. 2013 Jul 29;8(7):e70428. doi: 10.1371/journal.pone.0070428. Print 2013.

Supplemental Content

Loading ...
Support Center